Salbutamol in Congenital Myasthenic Syndrome: A Systematic Review
Open Access
- 11 December 2025
- journal article
- review article
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Abstract
Congenital myasthenic syndromes (CMS) are inherited disorders of neuromuscular transmission with few effective treatments. Salbutamol, a β2-adrenergicKeywords
This publication has 75 references indexed in Scilit:
- Severe congenital myasthenic syndromes caused by agrin mutations affecting secretion by motoneuronsActa Neuropathologica, 2022
- Diverse myopathological features in the congenital myasthenia syndrome with GFPT1 mutationBrain and Behavior, 2022
- A founder mutation in the GMPPB gene [c.1000G > A (p.Asp334Asn)] causes a mild form of limb-girdle muscular dystrophy/congenital myasthenic syndrome (LGMD/CMS) in South Indian patientsneurogenetics, 2021
- Congenital myasthenic syndrome caused by novel COL13A1 mutationsJournal of Neurology, 2019
- Recessive variants of MuSK are associated with late onset CMS and predominant limb girdle weaknessAmerican Journal of Medical Genetics Part A, 2018
- Presynaptic congenital myasthenic syndrome with altered synaptic vesicle homeostasis linked to compound heterozygous sequence variants in RPH3AMolecular Genetics & Genomic Medicine, 2018
- A severe congenital myasthenic syndrome with “dropped head” caused by novel MUSK mutationsMuscle & Nerve, 2015
- Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamolMuscle & Nerve, 2012
- Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok‐7 myastheniaMuscle & Nerve, 2011
- Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon‐subunit mutationsMuscle & Nerve, 2011